Loyal is a clinical-stage animal health company developing longevity drugs for dogs. By targeting the underlying mechanisms of aging, Loyal hopes to extend the lifespan of dogs and improve their quality of life as they age.

As a solo-founder, Celine has put an outlier level of grit and effort into willing this deep tech company into existence. With over $150M raised, the team currently has three drugs in development and is making progress toward approval from the FDA’s Center for Veterinary Medicine.